×
Both healthcare giants reported third-quarter 2026 results in recent weeks, but investor reactions diverged, reflecting different growth and risk profiles. JNJ delivered stronger pharmaceutical momentum but was pressured by slowing MedTech (medical technology) growth and a large talc litigation charge.
CNC is executing a faster margin recovery, with management raising full-year adjusted EPS guidance after a strong earnings beat, while MOH is earlier in its turnaround and still absorbing Medicaid margin pressure. Centene's shares have delivered substantially stronger relative performance over the past year, while Molina's rebound has been more modest and remains tied to a Medicaid rate cycle that is only beginning to turn.
Margin-led recovery, not volume growth: UnitedHealth is prioritizing profitability over membership, deliberately shrinking enrollment in Medicare Advantage and Medicaid to restore margins toward long-term targets. 2027 guidance is the near-term swing factor: Management plans to issue a fuller 2027 outlook before year-end, and consensus views the initial view of low-end, 13%–16% earnings growth as potentially conservative.
The central $490 stock price target is the arithmetic mean of nine verified, current analyst price targets reviewed for this article, rounded from a calculated average of roughly $493. At the latest verified close near $410.91, reaching $490 implies roughly 19% upside from current levels.
UnitedHealth Group shares climbed roughly 9% over the trailing 30 days, moving from about $371.90 to $406.97, as investors rewarded improving profitability. Third-quarter 2026 adjusted earnings per share of $4.69 beat consensus estimates and rose sharply from $2.92 a year earlier, while revenue of $112.7 billion was essentially flat year over year.
Aetna margin recovery is the dominant earnings driver, with the medical benefit ratio (MBR) — the share of premiums paid out for medical claims — improving sharply and management targeting Medicare Advantage margins of 3%–4% by 2028. Guidance has been raised twice in 2026 , lifting full-year adjusted EPS to a $7.90–$8.10 range and operating cash flow to at least $11.5 billion, with an initial 2027 EPS floor near $8.44.
The central $115 target is the rounded average of current analyst price targets — roughly $115.48 across about 27 analysts tracked by S&P Global. With CVS Health Corporation (CVS) trading near $90.25, reaching $115 implies upside of about 27%, a substantial move rather than an incremental one.
CVS Health shares were trading around $90 in late October, a modest single-digit advance of roughly 5% over the trailing 30 days after a pullback toward the mid-$80s. The stock remains well below its mid-summer levels, having declined roughly 13% over the past three months.
Divergent momentum: CNC has delivered a much stronger relative performance over recent months, while UNH has posted steadier, lower-beta gains as it executes a multi-year turnaround. Different business profiles: Centene is a managed care company concentrated in government-sponsored programs, whereas UnitedHealth combines insurance with its diversified Optum services and technology platform.
CI trades at a lower valuation with a forward price-to-earnings (P/E) ratio near 9 and a dividend yield above 2%, reflecting a value-oriented profile. UNH has shown stronger recent momentum, with improving medical cost trends and a raised full-year earnings outlook following its latest quarterly results.
ALHC dropped from $8.06 at the prior close to $7.39, down -8.31%, during regular trading hours. The slide follows Q3 results reported after the Oct. 29 close: revenue beat, but the company cut full-year adjusted EBITDA guidance to at least $100M (versus ~$147.8M consensus) and guided Q4 below expectations amid higher medical costs (MBR rose to 89.5%).
Third quarter 2026 revenue rose 36.7% year over year to about $1.36 billion, topping the roughly $1.31 billion consensus estimate. GAAP (Generally Accepted Accounting Principles) EPS (earnings per share) came in at -$0.04, in line with consensus but a reversal from a $0.02 profit in the same quarter last year.
CLOV is a fast-growing Medicare Advantage and physician-enablement technology company, while WTW is a diversified global advisory, broking, and solutions firm with steadier, more mature economics. Recent momentum clearly favors CLOV : it is riding rapid membership growth, a top-quality plan rating, and a shift toward GAAP profitability, whereas WTW has lagged the broader market in 2026.
Centene reported third-quarter 2026 adjusted diluted earnings per share (EPS) of $0.58, up 16% from $0.50 a year earlier and well ahead of Wall Street estimates. Total revenue reached $50.65 billion, rising 1.9% year over year and beating consensus forecasts by a wide margin.
HUM has delivered sharper recent momentum, buoyed by a decisive recovery in its Medicare Advantage Star Ratings, but carries a higher valuation and more concentrated risk profile. UNH offers a more diversified business spanning insurance and healthcare services, with a steadier, multi-quarter earnings turnaround and a long-running dividend.
ELV (Elevance Health) posted a stronger-than-expected third quarter, raising its 2026 adjusted earnings guidance and signaling at least 12% EPS (earnings per share) growth for 2027. UNH (UnitedHealth Group) is further along in its margin-repair turnaround, with a sharply improved medical care ratio and a third consecutive guidance increase this year.
CNC (Centene Corporation) is a government-focused managed care provider, while UNH (UnitedHealth Group) is a diversified healthcare giant spanning insurance and healthcare services. Centene has delivered stronger recent momentum, posting a sharp year-to-date advance as Medicaid and Marketplace margins recover, whereas UnitedHealth's gains have been steadier and driven by cost control rather than revenue growth.
CVS is executing a turnaround, having beaten earnings expectations for five consecutive quarters and raised its 2026 profit guidance after improving medical-cost controls. UNH is the larger, more diversified operator and has raised its full-year earnings outlook multiple times in 2026 as its insurance margins recover.
ALHC is a fast-growing, technology-enabled Medicare Advantage (privately administered Medicare) insurer for seniors, while UNH is the largest diversified U.S. healthcare company, spanning insurance and health services. The two operate at vastly different scales: UNH carries a market capitalization measured in the hundreds of billions of dollars, while ALHC is a smaller, higher-growth name with a multibillion-dollar valuation.
HUM has delivered sharp, catalyst-driven momentum in recent weeks, led by a dramatic recovery in Medicare Advantage Star Ratings. UNH has posted steadier, margin-led improvement, beating earnings and raising its full-year outlook multiple times.